D
Last Price
52 Week Range
CA$0.55 - CA$1.66
Next Earnings Date
-
Next Earnings Date
-
Last Price
Market Cap | CA$41.28M |
EV | CA$41.93M |
Shares Outstanding | 57.88M |
Beta | 1.34 |
Industry | Biotechnology |
Analyst Rating | - |
Analyst Target Price | - |
Number of Analysts | 0 |
P/E E | - |
P/Revenue E | - |
Revenue | - |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Revenue | - |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin E | - |
Net Profit Margin E | - |
ROE E | - |
ROCE | - |
DPS E | - |
Payout Ratio E | - |
Div. Yield E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
D
Defence Therapeutics Inc.
DTC
Sector
Healthcare
Industry
Biotechnology
CEO
Plouffe, Sebastien
Employees
Website
defencetherapeutics.comIPO Date
2021-05-10
Headquarters
7171 Rue Frederick-Banting, Montreal, Quebec, H4S1Z9, Canada
The last closing price of Defence Therapeutics (DTC) is CA$0.72, reflecting a +5.88% change from the prior session. Last updated: December 31, 2025 at 4:03 PM Eastern Time
Review the recent DTC stock performance trends:Past 1 Month: Defence Therapeutics (DTC) shares have -14.29%.Past 3 Months: The stock has +7.46%.Past 6 Months: DTC shares have +2.86%. Last updated: December 31, 2025 at 11:41 PM Eastern Time
Over the last year, Defence Therapeutics (DTC) has established a 52-week price range between a high of CA$1.66 and a low of CA$0.55. This metric is essential for assessing the stock's annual volatility. Last updated: December 31, 2025 at 11:41 PM Eastern Time
Defence Therapeutics (DTC) is considered a medium volatility stock. It has a beta of 1.34, which means it typically moves 1.34 times as much as the broader market. Over the past 52 weeks, DTC has traded within a CA$0.55 – CA$1.66 range. Last updated: December 31, 2025 at 11:41 PM Eastern Time
The current Defence Therapeutics (DTC) market capitalization is approximately CA$41.28M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Defence Therapeutics's market cap fluctuates with changes in its share price and share count. Last updated: December 31, 2025 at 11:41 PM Eastern Time
Defence Therapeutics (DTC) does not currently pay a dividend. Over the last twelve months (LTM), the company paid CA$0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future.
Based on the latest available analyst coverage, Defence Therapeutics (DTC) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: December 31, 2025 at 4:03 PM Eastern Time
Like other publicly traded stocks, Defence Therapeutics (DTC) shares are bought and sold on stock exchanges such as CNSX and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Defence Therapeutics (DTC) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.
At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add DTC to your watchlist.
Defence Therapeutics trades under the ticker symbol DTC on the CNSX stock exchange. The ticker DTC is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.
Defence Therapeutics (DTC) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Defence Therapeutics (DTC) stock peers based on overlapping products, services, and competitive dynamics:Cytophage Technologies (CYTO)Biomark Diagnostics (20B)Medicenna Therapeutics (MDNA)BriaCell Therapeutics (BCT)ME Therapeutics Holdings (METX)Helix BioPharma (HBP)enGene Holdings (ENGN) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Defence Therapeutics.
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.